Proton Pump Inhibitor Homogenous Suspensions: A Compounding Solution to Pediatric Gastroesophageal Reflux Disease
Author(s): Corsini Lindsay, Williams LaVonn A
Issue: Mar/Apr 2011 - Volume 15, Number 2
View All Articles in Issue
Page(s): 124-128
Download in electronic PDF format for $75
Abstract: In the pediatric patient, histamine2-receptor antagonists and/or proton pump inhibitors are recommended for effective therapy of gastroesophageal reflux disease. Proton pump inhibitors, a group of drugs whose main action is a pronounced and long-lasting reduction of gastric acid production, are more cost effective than histamine2-receptor antagonists because of long-term and enhanced treatment outcome. The compounding of proton pump inhibitors is an exacting procedure. Compounding pharmacists have the potential to provide optimal pharmacologic treatment of gastroesophageal reflux disease to a young population that requires special attention.
Related Keywords:
gastroesophageal reflux disease, GERD, children, infants, proton pump inhibitors, formulations, lansoprazole, omeprazole, pantoprazole, oral liquid suspensions
| Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Proton Pump Inhibitor Homogenous Suspensions: A Compounding Solution to Pediatric Gastroesophageal Reflux Disease
Corsini Lindsay, Williams LaVonn A
|
Mar/Apr 2011
Pg. 124-128
|
Basics of Compounding for Raynaud's Disease
Glasnapp Andrew
|
Jul/Aug 2003
Pg. 288-291
|
Omeprazole 1 mg/mL and 4 mg/mL in Humco Flavor Sweet Sugar-Free Oral Liquid
Allen Loyd V Jr
|
Jan/Feb 2019
Pg. 58
|
Compatibility of Flavoring Agents in Compounding Extemporaneous Omeprazole Oral Liquid
Chuong Monica, Taglieri Catherine A, Huang Szu Yu, Sariol Anthony, Kitigawa Reina, Barman Koushik, Mistry Amee, Harris Donna L, Kerr Stephen G
|
Nov/Dec 2019
Pg. 504-510
|
Lansoprazole 3-mg/mL Oral Suspension
Allen Loyd V Jr
|
May/Jun 2010
Pg. 246
|
Pantoprazole Sodium 2-mg/mL Oral Liquid
Allen Loyd V Jr
|
Sep/Oct 2006
Pg. 391
|
The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment
Meissner Svenja, Bansal Mahima, Dela Cruz Paula Donamae, Hanning Sara, Svirskis Darren
|
Mar/Apr 2020
Pg. 140-147
|
Stability of Omeprazole Extemporaneous Oral Solution in Chopin Base
Spennacchio Antonio, Lopedota Angela Assunta, la Forgia Flavia Maria, Fontana Sergio, Denora Nunzio, Lopalco Antonio
|
May/Jun 2023
Pg. 250-255
|
Pediatric Compounding: Coloring Outside the Lines
Preckshot John
|
Jan/Feb 2001
Pg. 6-8
|
Omeprazole 2-mg/mL Oral Liquid
Allen Loyd V Jr
|
Sep/Oct 2006
Pg. 389
|
To Flavor or Not to Flavor Extemporaneous Omeprazole Liquid
Chuong Monica C, Taglieri Catherine A, Kerr Stephen G
|
Nov/Dec 2017
Pg. 500-512
|
Treating Canine Hepatic Disease
Davidson Gigi S
|
May/Jun 2003
Pg. 188-191
|
Lansoprazole 3-mg/mL Oral Liquid
Allen Loyd V Jr
|
Jan/Feb 2007
Pg. 74
|
Compounding for a Pediatric Hospital
McElhiney Linda F
|
Nov/Dec 2005
Pg. 423-431
|
Lansoprazole 3-mg/mL in Ora-Blend Suspension
Allen Loyd V Jr
|
Sep/Oct 2022
Pg. 429
|
Compounding for Juvenile Idiopathic Arthritis and Other Pediatric Rheumatic Diseases
Harrington Amy, Williams LaVonn
|
Jul/Aug 2022
Pg. 293-296
|
Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients
Schotik Debora
|
Jan/Feb 2001
Pg. 9-12
|
Extended Stability of Morphine and Sildenafil for Oral Use in Infants and Young Children
Nahata Milap C
|
May/Jun 2016
Pg. 247-249
|
Stability of Omeprazole in SyrSpend SF Alka (Reconstituted)
Whaley Paul A, Voudrie Mark A II, Sorenson Bridget
|
Mar/Apr 2012
Pg. 164-166
|
Long-term Stability of Esomeprazole in 5% Dextrose Infusion Polyolefin Bags at 5°C ± 3°C after Microwave Freeze-thaw Treatment
Hecq Jean-Daniel, Rolin Catherine, Godet Marie, Gillet Patricia, Jamart Jacques, Galanti Laurence M
|
Nov/Dec 2015
Pg. 521-524
|
| Return to Top |
